Cardiovascular and cerebrovascular events among patients receiving omalizumab: Pooled analysis of patient-level data from 25 randomized, double-blind, placebo-controlled clinical trials

J Allergy Clin Immunol. 2017 May;139(5):1678-1680. doi: 10.1016/j.jaci.2016.12.953. Epub 2017 Jan 17.

Authors

Carlos Iribarren¹, Kenneth J Rothman², Mary S Bradley³, Gillis Carrigan³, Mark D Eisner³, Hubert Chen⁴

Affiliations

¹ Division of Research, Kaiser Permanente Medical Care Program, Oakland, Calif.
² RTI Health Solutions, Research Triangle Park, NC.
³ Genentech, Inc, South San Francisco, Calif.
⁴ Genentech, Inc, South San Francisco, Calif. Electronic address: chen.hubert@gene.com.

PMID: 28108337
DOI: 10.1016/j.jaci.2016.12.953

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Anti-Asthmatic Agents / adverse effects*
Anti-Asthmatic Agents / therapeutic use
Cardiovascular Diseases / epidemiology*
Cardiovascular Diseases / etiology
Cardiovascular Diseases / mortality
Cerebrovascular Disorders / epidemiology*
Cerebrovascular Disorders / etiology
Cerebrovascular Disorders / mortality
Child
Double-Blind Method
Humans
Hypersensitivity / epidemiology
Hypersensitivity / mortality
Hypersensitivity / therapy*
Omalizumab / adverse effects*
Omalizumab / therapeutic use
Placebo Effect
Randomized Controlled Trials as Topic
Survival Analysis

Substances

Anti-Asthmatic Agents
Omalizumab